Baseline analysis of renal function in the Diabetes Control and Complications Trial

Mark E. Molitch, Michael W. Steffes, Patricia A. Cleary, David M. Nathan

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


To determine whether there are relationships between nephropathy, retinopathy and putative risk factors at points very early in the development of long-term complications of IDDM, we have analyzed baseline data pertinent to nephropathy in the 726 subjects in the primary prevention cohort and the 715 subjects in the secondary intervention cohort of the DCCT. AER correlated positively with CCr and HbA1c in both cohorts and with degree of retinopathy and duration of IDDM in the secondary cohort. Within the secondary cohort only mean BP and HbA1c levels were significantly increased (P < 0.005) in the 73 subjects with AER ≥ 28 μg/24 hr compared to the 642 subjects with AER < 28 μg/24 hr. Stratification of all subjects in the secondary cohort showed significant associations (P < 0.001) between retinopathy level, AER, duration of diabetes at entry and entry HbA1c. Even very early in the development of retinopathy and nephropathy, there is a relationship between them and with level of metabolic control. The prospective studies of the DCCT are designed to answer the question of whether intensive diabetes treatment will affect the development and/or progression of retinopathy, and, possibly, of nephropathy.

Original languageEnglish (US)
Pages (from-to)668-674
Number of pages7
JournalKidney international
Issue number3
StatePublished - Mar 1993

Bibliographical note

Funding Information:
The DCCT is supported by the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, through coopera- tive agreements and a research contract. Additional support or techni-cal assistance was provided by the National Institute of Neurologic and Communicative Disorders and Stroke, the National Heart Lung and Blood Institute, the National Eye Institute, and the Division of Research Resources, National Institutes of Health. A complete list of organizations providing goods, services and/or discounts to the DCCT appears in Diabetes Care 10:1—19, 1987. This work was presented in part at the 50th Annual Meeting of the American Diabetes Association, Atlanta, June, 1990 [44].


Dive into the research topics of 'Baseline analysis of renal function in the Diabetes Control and Complications Trial'. Together they form a unique fingerprint.

Cite this